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Abstract
Background: A global definition of asthma control does not currently exist. The purpose of this
study was to validate two new guideline-based composite measures of asthma control, defined as
totally controlled (TC) asthma and well controlled (WC) asthma.
Methods: We used data from 3416 patients randomised and treated in the multi-centre Gaining
Optimal Asthma controL (GOAL) study. The criteria comprising the asthma control measures
were based on Global Initiative for Asthma/National Institutes of Health guidelines. This validation
study examined the measurement properties of the asthma control measures using data from run-
in, baseline, 12 and 52 weeks. Forced expiratory volume in 1 second (FEV1) and the Asthma Quality
of Life Questionnaire (AQLQ) were used as the reference criteria in the validation analysis.
Results: Both measures had good discriminative ability showing significant differences in FEV1 and
AQLQ scores between control classification both cross-sectionally and longitudinally (p < 0.001).
Overall both of the composite measures accounted for more of the variance in FEV1 after 52 weeks
than the individual components of each asthma control measure. Both of the reference criteria
were independently related to each asthma control measure (p < 0.0001). The measures also had
good predictive validity showing significant differences in FEV1 and AQLQ scores at 52 weeks by
control classification at 12 weeks (p < 0.0001).
Conclusion: The guideline-based composite asthma control measures of WC asthma and TC
asthma have good psychometric properties and are both valid functional indices of disease control
in asthma.
Background
The aim of asthma management, as endorsed by the pub-
lication of recent guidelines, is to achieve and maintain
effective control of the disease [1-3]. The effectiveness of
therapeutic interventions in asthma clinical trials is most
commonly evaluated using individual endpoints, such as
forced expiratory volume in 1 second (FEV1). However,
the assessment of these individual endpoints may lead to
an over-estimation of the level of asthma control achieved
[4] and may not reflect the wider overall impact of the dis-
ease on the patient [5]. In addition, therapeutic benefit is
frequently expressed in terms of the degree of change in
individual endpoints, rather than the achievement of a
concrete predefined clinical goal, such as the absence of
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key symptoms. While the former is a primary aim of
research-led studies largely designed to evaluate the effi-
cacy of new treatments, the latter is the primary clinical
objective in the day-to-day management of asthma.
Composite outcome measures that incorporate a range of
endpoints in a single definition allow a range of impor-
tant disease characteristics to be taken into account. In
chronic obstructive pulmonary disease this type of com-
posite measure has been shown to have superior predic-
tive properties, compared to the individual endpoints
comprising the composite [6].
Assessment of asthma control
Our aim was to validate two guideline-based measures of
asthma control. These tools had 'yes' or 'no' decision-
making properties because their primary function was as
an index of clinical status for use in asthma management.
The control criteria were based on definitions of asthma
control in recently published guidelines, including Global
Initiative for Asthma [3,7,8]. Totally controlled (TC) and
well controlled (WC) asthma include seven endpoints, as
detailed in Table 1. The evaluation of daytime symptoms
and frequency of rescue β2-agonist medication are well-
accepted measures for detecting deterioration of asthma
[11], and impending exacerbations [12]. The presence of
night-time awakening [13] or an emergency visit are
important but different indicators of change in asthma
status. Adverse events are included as a 'cost' of asthma
control in the reference guidelines and were included in
order to remain consistent with these (see Table 1). Morn-
ing peak expiratory flow (PEF) is considered to serve as an
objective measure of asthma control supplementary to
that of symptoms [9,10,14,15]. Any one of these criteria
alone is considered insufficient in the definition of
asthma control because although not independent of one
another, each endpoint contributes unique information
to the overall assessment [11,16-18].
The GOAL study specified two target levels of control (TC
and WC) because, while suggesting that complete absence
of symptoms of asthma was possible (TC), the GINA
guidelines suggest that 'minimal' daytime symptoms and
β2-agonist use are acceptable in 'controlled asthma' (WC).
WC weeks were defined by achievement of all the speci-
fied criteria for that week. Asthma control was assessed
over an 8-week period prior to each clinic visit. TC or WC
asthma was achieved if the patient had at least 7 out of 8
weeks in that control state. Emergency visits, exacerba-
tions or treatment-related adverse events during the 8-
week period resulted in automatic failure of either TC or
WC status for the whole period. TC asthma was defined as
no symptoms or rescue medication use whereas WC
asthma allowed a low level of symptoms and rescue med-
ication use during the assessment period [19].
A set of pragmatic, clinical and psychometric criteria have
been described as the minimum standards required in
developing tools of this kind [20]. It is essential that the
effectiveness of a new measure, such as a composite end-
point, be judged against widely accepted standards for the
development of such tools. Therefore it is the responsibil-
ity of the developers to demonstrate that the tool has three
essential properties. That it is reliable, i.e. that it can con-
sistently yield the same results when administered on sev-
eral occasions to the same stable patients and that it can
discriminate between patients with differing levels of dis-
ease [21,22]. That it is valid, i.e. that it is measuring what
it claims to measure. Lastly, that it has sufficient sensitiv-
ity, i.e. that it responds to changes in the underlying dis-
ease [22-24]. Rather than relying on a single established
reference measure of disease activity against which to test
the properties of the new instrument, we used multiple
reference measures that together provide a profile of psy-
chometric performance [24-27].
The aim of this study was to examine the reliability, valid-
ity and sensitivity of the two new guideline-based com-
posite measures of control, TC and WC asthma, used in
the Gaining Optimal Asthma controL (GOAL) study [19].
Methods
Study and population
The GOAL study was a 1-year, randomised, stratified, dou-
ble-blind, parallel-group trial comparing the efficacy of
salmeterol/fluticasone propionate with fluticasone propi-
onate alone in achieving two composite measures of
asthma control. The study was conducted in 326 centres
across 44 countries. Full details of the study are published
elsewhere [19] and the study design is shown in Figure 1.
During the 4-week run-in period patients who did not
achieve at least two WC weeks were randomised to the
study. During Phase I, the dose-escalation phase, treat-
ment was 'stepped up' every 12 weeks until TC asthma was
achieved or the highest dose of study drug reached.
Patients entered Phase II either after achieving TC asthma
or after 12 weeks on the maximum dose of study medica-
tion. During Phase II, patients remained on the dose at
which they achieved TC asthma or the maximum dose of
study medication until the end of the 1-year double-blind
treatment period. Patients who failed to achieve TC
asthma in Phase I were reassessed at the end of Phase II
(Weeks 44–52).
Patients recruited to the study had at least a 6-month his-
tory of asthma and an improvement in FEV1 ≥ 15% (and
≥ 200 ml) after inhalation of a short-acting β2-agonist. The
mean age of patients in the study was 40.4 (range, 9–83),
they had a mean baseline FEV1 of 74.47% of predicted
(standard deviation, 18.55) and 42% were male. 5068Respiratory Research 2007, 8:26 http://respiratory-research.com/content/8/1/26
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patients were screened and 3416 were randomised to the
study and treated.
Study protocol and outcomes
Asthma control was assessed over the 4-week run-in
period and 8 weeks prior to each clinic visit at 12, 24, 36
and 52 weeks. For the purpose of validation we used data
from the run-in period, baseline, 12 and 52 weeks. At the
clinic visits, morning pre-dose FEV1, information regard-
ing exacerbations, emergency visits and adverse events
were recorded. In 197 centres in 16 countries health-
related quality of life (HRQoL) was assessed using the
Asthma Quality of Life Questionnaire (AQLQ) [28]. The
AQLQ is a 32-item measure with established validity and
reliability in asthma clinical trials [29-31]. It is scored
from 0 (maximum impairment) to 7 (no impairment)
and a within-subject change in score of ≥ 0.5 is considered
the minimal clinically important difference [32,33].
Validation analysis
Validation of composite endpoints is not straightforward
when considering a measure that produces a 'state' rather
than a 'score'. Traditional psychometric tests largely apply
parametric statistics to continuous outcome variables.
Given that our outcomes are not scores that can be
defined as continuous variables, we have used the follow-
ing methods to assess the validity of the measures of
asthma control. Treatment was constant for all patients
during Weeks 5–12 of Phase I, so the validation tests have
focused on data from this period. The validation tests
have been carried out on combined data from both treat-
ment groups. In addition, since we are validating each of
the composite measures of TC and WC asthma the valida-
tion tests have focused on comparisons between patients
achieving the given control state and those who did not.
For tests of sensitivity against the reference criteria we have
used change from baseline data for the maximum possi-
ble period, i.e. to the end of the study at 52 weeks.
Construct validity
Traditionally, the construct validity of a new measure
would be evaluated using a test such as Cronbach's Alpha
to assess internal consistency, i.e. the degree to which all
components contribute to the overall measure. In the
absence of an overall score for the measure of asthma con-
trol, it was not possible to calculate the Alpha statistic.
However, an assumption of composite endpoints in gen-
eral is that all elements make a relatively independent
contribution to that definition. We tested this assumption
by examining the correlations amongst the seven criteria
using the phi coefficient for dichotomous variables [26].
Reliability
Reliability would normally be tested using the intraclass
correlation coefficient to establish within versus between
occasion error variance. However, this was not possible
during the study as a patients asthma control status was
expected to fluctuate during the run-in period and to
improve whilst on study medication. Therefore there was
no predictable period of stability in which to test reliabil-
ity at the group level.
Validity
In the absence of a gold standard against which to com-
pare the composite measures of asthma control we used
two reference criteria evaluated during the 1-year trial:
percent predicted FEV1 as an objective index of airflow
limitation; and the AQLQ as an established reference cri-
Table 1: Definitions of well controlled (WC) and totally controlled (TC) asthma based on Global Initiative for Asthma (GINA)/
National Institutes of Health (NIH) guideline aims of treatment [3, 8]
Goals of GINA/NIH Totally controlled Well controlled
Each week all of: Each week two or more of:
Daytime symptoms Minimal (ideally no) None ≤ 2 days symptom score > 1
Rescue β2-agonist use Minimal (ideally no) None Use on ≤ 2 days and ≤ 4 occasions 
per week
Morning peak expiratory flow Near normal ≥ 80% predicted every day ≥ 80% predicted every day
All of:
Night-time awakening Minimal (ideally no) None None
Exacerbations Minimal (infrequent) None None
Emergency visits No None None
Treatment-related adverse 
events
Minimal None enforcing change in asthma 
therapy
None enforcing change in asthma 
therapy
TC and WC asthma were defined as achievement of all of the specified criteria for that week. Asthma control was achieved if the patient recorded 
7 out of 8 controlled weeks prior to each clinic visit. Baseline control was assessed over a 4-week period. Predicted peak expiratory flow (PEF) was 
calculated based on the ECSC standards for patients 18 years and older and on the Polgar standards for patients 12–17 years old.
Symptom score: 1 was defined as 'symptoms for one short period during the day'. Overall scale: 0 (none) – 5 (severe).
Exacerbations were defined as deterioration in asthma requiring treatment with an oral corticosteroid or an emergency department visit or 
hospitalisation.Respiratory Research 2007, 8:26 http://respiratory-research.com/content/8/1/26
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Study design for (a) Strata 1 and 2, and (b) Stratum 3 Figure 1
Study design for (a) Strata 1 and 2, and (b) Stratum 3. Following a 4-week run-in period, patients were randomised to receive 
either salmeterol/fluticasone propionate (SFC) or fluticasone propionate (FP) alone and stratified according to inhaled corti-
costeroid (ICS) use during the 6 months before screening: Stratum 1, no ICS; Stratum 2, 500 μg beclometasone dipropionate 
daily or equivalent; or Stratum 3, > 500–1000 μg beclometasone dipropionate daily or equivalent.Respiratory Research 2007, 8:26 http://respiratory-research.com/content/8/1/26
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terion for HRQoL that represents the impact of asthma on
global health and well-being. Neither of these two meas-
ures formed part of the composite endpoints and were
therefore appropriate as external reference criteria. How-
ever, the AQLQ was only evaluated in a sub-sample of the
total population so preference is given to comparisons
with percent predicted FEV1 where a larger proportion of
the overall population provided information.
Validity of both the TC and WC definitions were evaluated
cross-sectionally using an analysis of variance model to
compare differences in the reference criteria values
between patients who achieved the control status and
those who did not. Longitudinal validity of both defini-
tions was similarly tested by examining differences in
change from baseline in the reference criterion between
patients who achieved the control status and those who
did not.
To evaluate the overall discriminative properties of the
composite measures of asthma control we evaluated the
discriminative properties of each composite endpoint
(TC/WC) against the discriminative properties of the
seven components of the composite endpoints. This was
done through comparing the variation in percent pre-
dicted FEV1 attributed to the composite measures against
the variation attributed to each component of the com-
posite measures individually. The validity of the compos-
ite measures depends on the ability to discriminate
between patients more effectively than the individual ele-
ments of the composite.
Finally, if the measure of asthma control summarises a
range of aspects of disease impact, it should be related to
each of our external reference criteria. A logistic regression
model of control status with the reference criterion as fac-
tors was used to show how each reference criterion was
related to control status, the amount of variation in the
control status the two reference criterion accounted for
was also assessed.
Predictive validity
To test the ability of the asthma control measures to pre-
dict future disease activity the Week 52 percent predicted
FEV1 values were compared between patients who met the
control criteria at Week 12 and those who did not. This
was done using an analysis of variance model for each
asthma control measure, and was repeated for the Week
52 AQLQ scores.
Results
Construct validity
Correlations between components of each control meas-
ure at Week 12 were moderate to weak (Table 2). β2-ago-
nist use, night-time awakenings and daytime symptoms
were, as expected, the most strongly correlated (r = 0.37 to
0.68). Results indicate that the individual criteria of the
composite endpoint are relatively independent of each
other. Very small correlations between emergency visits
(EVs) and adverse events (AEs) were to be expected given
the small number of each of these events (between Weeks
5 and 12 there were 91 EVs and 2 AEs). The relatively
strong correlation between exacerbations and EVs was to
be expected given that most of the emergency room visits
were due to an exacerbation of patients' conditions.
Discriminative properties
The asthma control measures had good discriminative
properties when compared with percent predicted FEV1 at
Week 12 (Figure 2a) and change in percent predicted FEV1
from baseline to Week 52 (Figure 2b). Patients achieving
TC asthma had higher percent predicted FEV1 values and
showed greater improvements over 52 weeks compared to
those with 'not' TC (NTC) asthma (p < 0.001). Similar
results were seen for the WC definition. FEV1 improve-
ments in patients with TC or WC asthma were nearly twice
those of patients with NTC or 'not' WC (NWC) asthma,
respectively.
The asthma control measures also had good discrimina-
tive properties when compared with AQLQ scores at Week
12 (Figure 3a) and change in AQLQ scores from baseline
to Week 52 (Figure 3b). Higher (better) AQLQ scores and
greater improvement in scores were associated with
achieving control status compared to not achieving con-
trol status, for both TC and WC asthma. The differences
between the mean AQLQ scores at Week 12 and the mean
change from baseline scores at Week 52 were statistically
significant (p < 0.001) for both TC and WC asthma com-
pared to NTC and NWC, respectively.
We further explored the relationship between asthma con-
trol status and percent predicted FEV1 by comparing per-
cent predicted FEV1 for those patients achieving control
both overall and for each of the individual asthma control
components at Week 52, for both TC and WC asthma.
Model estimates for overall control status and the individ-
ual criteria are shown for patients with TC vs NTC asthma,
and WC vs NWC asthma in Table 3. The amount of vari-
ance (R2) in percent predicted FEV1 at Week 52 accounted
for by overall control status was greater than that attribut-
able to the individual control status components (TC =
6%, WC = 5%), with the exception of PEF where the
higher R2 value was predictably attributable to the strong
relationship between these two measures of airflow limi-
tation. Results suggest that the composite asthma control
have measures better discriminative properties compared
to the individual asthma control status components
alone.Respiratory Research 2007, 8:26 http://respiratory-research.com/content/8/1/26
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To test the ability of the asthma control definitions to
summarise other measures of disease activity, we exam-
ined the relationship between asthma control status and
the two reference criterion: percent predicted FEV1 and
AQLQ score. The model showed that both reference crite-
ria were independently significantly related to asthma
control status (p < 0.0001). The two criteria together
accounted for 7% of the variance in TC asthma and 19%
of the variance in WC asthma. This suggests that although
these two measures of disease activity are summarised by
both definitions of asthma control, the majority of the
variance (TC = 93% and WC = 81%) is attributable to
other unidentified factors.
Predictive validity
To test the ability of asthma control to predict future
markers of disease activity, we compared asthma control
status at Week 12 to percent predicted FEV1 and the AQLQ
score at Week 52 (Table 4). The models show that asthma
control status has good predictive validity indicating a sig-
nificant difference in mean scores at Week 52 for both TC
and WC patients against NTC and NWC patients, respec-
tively.
Discussion
The results of this study provide evidence that the com-
posite measures of TC and WC, derived from interna-
tional guidelines, are valid instruments for defining and
measuring asthma control. Although recent guidelines [1-
3] have suggested specific criteria for assessing asthma
control there are a limited number of measures available
for assessing comprehensive asthma control [14,34,35].
Individual criteria alone do not sufficiently encompass
the full spectrum of the impact of the disease on patients
and a more global approach to the definition of control
was required [5]. There was a need for a simple to use, evi-
dence-based, practical measure that indicated when a
patient's asthma had achieved the target level/s of control
suggested in clinical guidelines, and that might serve as a
goal for treatment of patients in clinical practice.
We evaluated the psychometric properties of TC and WC
definitions as measures of asthma control in several ways.
In order for each individual component to make a neces-
sary and sufficient contribution to the TC and WC com-
posite definitions of asthma control they should each be
relatively independent of each other [26]. We showed that
correlations among the individual components were low
to moderate, supporting the independence of each ele-
ment's contribution to the overall definition. This is com-
mensurate with what we would expect from such
measures, given that strong correlations would suggest
that some of the criteria were providing redundant infor-
mation and were therefore not necessary components of
the composites. Traditional measures of construct valid-
ity, such as a Cronbach's alpha, were not calculable with
this type of outcome measure. However, we believe that
we have demonstrated that the TC and WC measures have
construct validity with the tests we have performed.
In order for the measures of asthma control to have prac-
tical value in terms of clinical practice, it is essential that
they have the ability to discriminate between patients
with differing levels of asthma both cross-sectionally and
longitudinally. One of the difficulties of assessing the
validity of composite measures is the requirement for
markers of disease activity that are not already elements of
the composite as sources of comparison – also known as
reference measures. We were able to evaluate the discrim-
Table 2: Correlation between control status criteria at Week 12
β2 use PEF N-T awake Exac. EV AE
Well controlled
Symptoms 0.52 0.23 0.37 0.13 0.13 0.05
β2 use 0.28 0.46 0.13 0.11 0.03
PEF 0.24 0.10 0.08 0.04
N-T awake 0.12 0.09 0.04
Exac. 0.49 0.13
EV 0.18
Totally 
controlled
Symptoms 0.68 0.25 0.38 0.09 0.08 0.01
β2 use 0.26 0.45 0.10 0.09 0.01
PEF 0.24 0.10 0.08 0.04
N-T awake 0.12 0.09 0.04
Exac. 0.49 0.13
EV 0.18
Symptoms = Daytime symptoms; β2 use = Use of rescue β2-agonist; PEF = Peak expiratory flow rate; N-T awake = Night time awakening; Exac. = 
exacerbations; EV = Emergency visits; AE = Treatment-related adverse events.Respiratory Research 2007, 8:26 http://respiratory-research.com/content/8/1/26
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(a) Percent predicted forced expiratory volume in 1 second (FEV1) by control status at Week 12 (mean and 95% confidence  interval) and (b) Change in percent predicted FEV1 from baseline to Week 52 by control status at Week 52 (mean and 95%  confidence interval) Figure 2
(a) Percent predicted forced expiratory volume in 1 second (FEV1) by control status at Week 12 (mean and 95% confidence 
interval) and (b) Change in percent predicted FEV1 from baseline to Week 52 by control status at Week 52 (mean and 95% 
confidence interval). Patients with TC asthma has significantly higher FEV1 % predicted compared to those with NTC asthma, 
and WC patients had significantly higher FEV1 % predicted compared to those NWC. Key: TC: Patients with totally controlled 
asthma. NTC: Patients with well controlled or not well controlled asthma. WC: Patients with either well controlled or totally 
controlled asthma. NWC: Patients with not well controlled asthma. Figures in brackets are number of patients per group.
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(a) Asthma Quality of Life Questionnaire (AQLQ) score by control status at Week 12 (mean and 95% confidence interval) and  (b) Change in AQLQ score from baseline to Week 52 by control status at Week 52 (mean and 95% confidence interval) Figure 3
(a) Asthma Quality of Life Questionnaire (AQLQ) score by control status at Week 12 (mean and 95% confidence interval) and 
(b) Change in AQLQ score from baseline to Week 52 by control status at Week 52 (mean and 95% confidence interval). 
Patients with TC asthma has significantly higher AQLQ scores compared to those with NTC asthma, and WC patients had sig-
nificantly higher AQLQ scores compared to those NWC. Key: TC: Patients with totally controlled asthma. NTC: Patients with 
well controlled or not well controlled asthma. WC: Patients with either well controlled or totally controlled asthma. NWC: 
Patients with not well controlled asthma. Figures in brackets are number of patients per group.
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inative properties of the TC and WC measures against two
established measures of disease activity. FEV1 is a measure
of airflow limitation in airways disease and the AQLQ
score is a measure of quality of life in asthma as measured
by patients. These two indices may be considered repre-
sentative of different elements of disease activity given the
widely reported low correlations between FEV1 and qual-
ity of life measures [36-39] and the poor relationship
between change in FEV1 and decline in overall health [40].
Using these two independent reference criteria we have
demonstrated that the measures of TC and WC asthma
have good cross-sectional and longitudinal discriminative
properties when compared against other markers of dis-
ease activity.
We have further confirmed the discriminatory properties
of the TC and WC measures by demonstrating that they
have a greater ability to discriminate between levels of per-
cent predicted FEV1 severity compared to the individual
criteria alone. The ability of the control measures to
encompass a range of markers of disease activity was
shown by its independent relationship to both FEV1 and
AQLQ scores. Moreover, both of these reference criteria
combined accounted for less than 10% of the variability
in asthma control, suggesting that the TC and WC meas-
ures encompass more than just these two elements and in
fact reflect a more global definition of asthma control.
For the purpose of managing asthma in the individual
patient and for evaluating new treatments in clinical trials,
it is preferable for any new measure to have predictive
validity. In other words, that it has the ability to reliably
predict future changes in disease activity. We have shown
that the measures of TC and WC asthma 12 weeks into the
GOAL study differentiate between FEV1 and AQLQ scores
1 year later and hence that they have good predictive
validity, at least within the treatment conditions of the
GOAL study, where treatment was increased and then
maintained for the duration of the study.
A limitation of the current validation of these control
measures is that it is restricted by the design and parame-
ters recorded in the GOAL study on which it is based.
Diary card recall was limited to 1 week and the study
Table 3: Relationship between overall control status or control status criteria and percent predicted FEV1at Week 52
Control status Model Estimate (standard error) p-value R2
Totally controlled Overall 94.36 (0.639) < 0.0001 0.06
Symptoms 90.22 (0.555) < 0.0001 0.02
N-T awake 88.04 (0.416) < 0.0001 0.01
β2 use 90.23 (0.514) < 0.0001 0.03
PEF 93.52 (0.429) < 0.0001 0.17
Exac. 87.18 (0.373) 0.02 0.00
EV 87.10 (0.375) 0.4 0.00
Well controlled Overall 90.41 (0.459) < 0.0001 0.05
Symptoms 88.58 (0.419) < 0.0001 0.02
N-T awake 88.04 (0.416) < 0.0001 0.01
β2 use 89.75 (0.446) < 0.0001 0.04
PEF 93.52 (0.429) < 0.0001 0.17
Exac. 87.18 (0.373) 0.02 0.00
EV 87.10 (0.375) 0.4 0.00
Symptoms = Daytime symptoms; N-T awake = Night time awakening; β2 use = Use of rescue β2-agonist; PEF = Peak expiratory flow rate; Exac. = 
exacerbations; EV = Emergency visits; AE = Treatment-related adverse events.
Table 4: Predicting Asthma Quality of Life Questionnaire (AQLQ) score and percent predicted forced expiratory volume in 1 second 
(FEV1) at Week 52 from control status at Week 12
AQLQ score Percent predicted FEV1
Mean Difference p-value Mean Difference p-value
Totally 
controlled
Yes 6.48 0.63 < 0.0001 95.7 9.7 < 0.000
No 5.84 86.0 1
Well controlled Yes 6.34 0.67 < 0.0001 91.5 6.9 < 0.000
No 5.67 84.6 1Respiratory Research 2007, 8:26 http://respiratory-research.com/content/8/1/26
Page 10 of 11
(page number not for citation purposes)
recruited patients with poorly controlled asthma. The
validity of the measures over longer recall periods with
different populations would have to be re-established; in
the event that the guidelines are updated in accordance
with advances in research, the control measures would
similarly need to be adjusted and revalidated.
The control measures evaluated in this study include
patient-reported subjective endpoints (e.g. symptom
score) and a patient-reported measure of lung function.
They do not, however, include markers of asthma patho-
physiology or measures of lung function taken in the
clinic. Asthma is a complex entity comprising a range of
factors and although it is important to evaluate the physi-
ological features of asthma, it is equally important to take
into account subjective measures, as these influence serv-
ice use, effective self-management and compliance. Our
understanding of asthma and our ability to control it are
enhanced by both perspectives.
We have demonstrated that this instrument has good psy-
chometric properties and that it is effective as a tool
designed to aid clinical management. These measures of
asthma control were designed to be consistent with GINA
guidelines and therefore the component endpoints were
not selected according to the principles of classical test
theory, e.g. by using principal components analysis [24-
27]. Similarly, because the main aim of the measures was
to serve as an index of achieved control, a graded scoring
system was not deemed a necessary function. It is
acknowledged, however, that for other clinical uses, such
as the evaluation of disease progression or response to a
new treatment, there are advantages in using a quantifia-
ble rather than categorical outcome measure. Categorical
outcome measures are less useful for clinical purposes as
they are not able to detect subtle changes in the compo-
nents of asthma (for example, a small improvement or
deterioration in PEF or symptoms), particularly in
patients that do not achieve the threshold level of control
(TC or WC).
The Asthma Control Test [15], the Asthma Control Ques-
tionnaire (ACQ) [35] and Asthma Control Scoring System
[20] are examples of measures that include composites of
endpoints and provide numeric scores indicating asthma
control status. Each has undergone a measure of valida-
tion in different clinical and research settings and are
offered as an alternative to the GINA categorical measure
of control in the latest version of the GINA guidelines.
However, unlike TC and WC, none is based directly on,
nor has sought to validate, the endpoints and goals con-
tained in the guidelines, which was the purpose of the cur-
rent study.
A limitation of many composite measures, including
those evaluated in the present study, is the fact that each
component endpoint assumes equal importance in either
the categorisation or contribution to the overall score. The
weighting of the component endpoints in composite
measures is an issue that requires further research: there is
a need for a measure of asthma control that is guideline-
based, sensitive, valid and reliable; that includes validated
cut-points for major control milestones; and reflects the
relative importance of component parameters.
Conclusion
In conclusion, this validation study has shown that the
psychometric properties of the asthma control measures
of TC and WC asthma, as used in the GOAL study, are con-
sistent with an instrument that has good reliability, dis-
criminative ability and predictive validity. These control
measures are valid functional indicators of clinical status
that can be used in the evaluation of the efficacy of asthma
treatments and the overall management of patients with
asthma.
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